Rady Children’s Institute Partners with Sidra Medicine to Launch Global Newborn Genome Screening

Rady to Enter an International Partnership with Sidra Medicine

Announcement

Rady Children’s Institute for Genomic Medicine (RCIGM) entered into a collaboration with Sidra Medicine, an excellent specialty healthcare organization for women, young people, and children in the state of Qatar. The partnership motive is to execute RCIGM’s genome-related newborn screening program named ‘BeginNGS’. Sidra Medicine is the first international organization to join the beginNGS consortium.

With this partnership, the beginNGS program will expand the idea to health equity and, via the execution of genetic causes, add disease and pilot studies to the beginNGS newborn screening platform, which is designed to deliver the best to the needs of the regional community.

Sidra as a Potential Partner to the RCIGM Program

Sidra Medicine’s division of genomic and genetic medicine is leading as the prominent genomic medicine research organization in the region. The organization provides advanced care for all ages with rare or inherited genetic conditions. With the remarkable leadership of Dr. Ammira AI-Shabeeb Akil, a lead of the metabolic and mendelian clinical-translational research programs and PHD EMBA principal investigator and head of the precision genomics and translational omics lab at Sidra Medicine, she built a progressive future for herself and her organization. She supported the utmost to make the company rank as the country’s first highest newborn genome screening initiative. This partnership will help to upscale the addressing of genetic disease and provide on-time interventions that protect or reduce the suffering among children.

Views and Statements from the Company Leaders

MD, DSc, president and CEO of RCIGM, Stephen Kingsmore said, “The international expansion is crucial for our understanding of the indications of rare disease across various geographies and to address accurate available treatments on or before the onset of symptoms. It is one of our shared visions for the state of Qatar to lead as the first country in the world to bring the benefits of newborn therapies for extreme childhood disease accessible to every citizen.”

Phd, vice chair of beginNGS and deputy head of diagnostics at Alexion, Tom Defay said, “Surviving with a rare disease is challenging and worst, but by reducing the weight of the diagnostic odyssey, we can accelerate the advancement of health equity solutions for genetically related rare disease patients and their families. We are excited to contribute to the beginNGS consortium and its members advancing to the vast reach of complex diagnostic tools. This led to the first step in the way to treatment and care.”